IONIS PHARMACEUTICALS INC

Drug pipeline (12)

Asset	Stage	Revenue	Trials	Status
DONIDALORSEN SODIUM	approved	—	0	—
OLEZARSEN SODIUM	approved	—	0	—
ZILGANERSEN	approved	—	1	approved
Ulefnersen	phase3	—	1	active
COFIRASERSEN	phase2	—	1	terminated

Revenue is the latest reported period from SEC filings. A combination product's amount appears on each of its constituent assets, so those rows are not additive.

Clinical trials (109)

NCT ID	Phase	Status	Start	Completion	Sponsor name	Title
NCT00002355	—	completed	—	—	Ionis Pharmaceuticals, Inc.	A Comparison of ISIS 2922 Used Immediately or Later in Patients With Cytomegalovirus (CMV) of the Eyes
NCT03647228	phase1	completed	2018-12-13	2020-10-13	Ionis Pharmaceuticals, Inc.	A Phase 1/2a Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses of IONIS-ENaCRx in Healthy Volunteers and Patients With Cystic Fibrosis
NCT00002156	phase2	completed	—	—	Ionis Pharmaceuticals, Inc.	A Randomized Comparison of Intravitreal ISIS 2922 Plus Ganciclovir Versus Ganciclovir as Treatment for Patients With Cytomegalovirus Retinitis ( CMVR )
NCT02312011	phase1_2	completed	2014-12-01	2016-07-01	Ionis Pharmaceuticals, Inc.	A Safety andTolerability Study of Multiple Doses of ISIS-DMPKRx in Adults With Myotonic Dystrophy Type 1
NCT02476019	phase2	completed	2015-06-01	2016-07-01	Ionis Pharmaceuticals, Inc.	A Safety, Tolerability, PK, and PD Study of Once Weekly ISIS-FGFR4RX SC in Obese Patients

FDA applications (3)

Application

Type

Applicant

Products

NDA 218614

NDA

IONIS PHARMACEUTICALS INC

NDA 219407

NDA

IONIS PHARMACEUTICALS INC

NDA 220210

NDA

IONIS PHARMS INC